Palisade Bio
PALI
7 hedge funds and large institutions have $38.8M invested in Palisade Bio in 2015 Q1 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, reducing their positions, and 1 closing their positions.
28% more call options, than puts
Call options by funds: $723K | Put options by funds: $567K
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0% less ownership
Funds ownership: 0% → 0% (-0%)
13% less funds holding
Funds holding: 8 → 7 (-1)
31% less capital invested
Capital invested by funds: $56.2M → $38.8M (-$17.4M)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 1
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FAM
Fred Alger Management
New York
|
-$3.71M |
| 2 |
SIM
SSI Investment Management
Los Angeles,
California
|
-$269K |
| 3 |
ERIM
Eagle Ridge Investment Management
Stamford,
Connecticut
|
-$122K |
| 4 |
MAA
Managed Account Advisors
Jersey City,
New Jersey
|
-$52K |
| 5 |
First Manhattan
New York
|
-$27K |
PALI Hedge Fund Activity: Q1 2015 in Review
7 of the 3,752 institutional investors tracked by Wall St. Rank reported a position in Palisade Bio (PALI) for Q1 2015, worth a combined $38.8M — down 31% from $56.2M a quarter earlier.
Sellers outnumbered buyers: 1 fund closed out of PALI and 0 opened new positions — a net loss of 1 holder — while 0 trimmed existing stakes and 0 added.
The largest seller was Fred Alger Management, exiting entirely with an estimated $3.71M sold.
- 7 institutional investors held Palisade Bio (PALI) as of Q1 2015, down from 8 in Q4 2014.
- Funds reported $38.8M of Palisade Bio stock for Q1 2015, down 31% quarter-over-quarter.
- 0 funds opened new Palisade Bio positions in Q1 2015 and 1 closed out, a net change of -1 holder.
- The largest Palisade Bio seller in Q1 2015 was Fred Alger Management, an estimated $3.71M sold.
Based on aggregated 13F filings for Q1 2015.